Transaction #31374 · Form 4 · 0001940272-26-000022
InMed Pharmaceuticals Inc. · Purchase · Common Shares
InMed Pharmaceuticals Inc. · Transacted October 2, 2026 · Filed October 5, 2026
What does this filing report?
An SEC Form 4 filing for InMed Pharmaceuticals Inc. records a purchase involving Common Shares on October 2, 2026. The reported quantity was 8,307. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- InMed Pharmaceuticals Inc.
- Company CIK
- 0001728328
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 8,307
- Reported price
- 1.33
- Reference value
- 11,048.31
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 916,839
- Ownership description
- See Footnote
- SEC acceptance time
- Oct 5, 2026, 5:11 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Schneeberger Daniel ↗
10% owner
CIK 0001861120
- ADAR1 Capital Management, LLC ↗
10% owner
CIK 0001940272
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F2
- The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
- F3
- For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.